95 filings
8-K
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
8-K
CADL
Candel Therapeutics Inc
9 Apr 24
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
8:30am
8-K
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
S-8
CADL
Candel Therapeutics Inc
28 Mar 24
Registration of securities for employees
8:16am
10-K
2023 FY
CADL
Candel Therapeutics Inc
Annual report
28 Mar 24
8:00am
8-K
8grgumv
28 Mar 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
7:45am
8-K
zf6lwzfctb m32801
6 Mar 24
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
8:00am
424B5
s27qssal1wtymaxdkgh
13 Feb 24
Prospectus supplement for primary offering
9:00am
8-K
15z1vc92 8z
13 Feb 24
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
7:45am
8-K
lvu2pff06 0j8ewzeohf
12 Jan 24
Departure of Directors or Certain Officers
4:30pm
8-K
p8as5n6n5l qbrog717
3 Jan 24
Other Events
8:30am
8-K
0doh97 lpariukv1p
14 Dec 23
Departure of Directors or Certain Officers
6:33pm
8-K
33zjm ev0
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
8-K
r3ln ygrmaf3p69bqf8
28 Nov 23
Cost Associated with Exit or Disposal Activities
9:00am
8-K
38hle g2pgaf2lt
21 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
1iyzv9ajfc h4h
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
8-K
jtp3 ri8bjxm52t5pk7q
6 Nov 23
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
8:53am
8-K
v4t 4vrv0bdj
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
8-K
59i2j7pdy7r790c5u9wi
18 Oct 23
Regulation FD Disclosure
11:31am